Zenas BioPharma (ZBIO)

• Market cap: $1.39B
• 1 day: 5.71%
• 5 days: 15.48%
• 1 month: 33.38%
• 3 months: 88%
• 6 months: 155.7%
• Year to date: 228.63%
• 1 year: 41%
• 5 years: 63.14%
• 10 years: 63.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130